Standing Order
All companies

Biotech

Beam Therapeutics Inc.

BEAMNASDAQpure-play
Market cap$3.4B
Conviction3/ 5
HQCambridge, Massachusetts, USA

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 180d

$32.93

+36.9%

Thesis

Beam Therapeutics pioneers base editing, a precise single-letter approach to genetic correction that avoids double-strand breaks. Its pipeline spans both ex vivo and in vivo programs across genetic disease.

Catalysts

  • BEAM-101 sickle cell data and progress
  • In vivo base-editing program readouts
  • Validation of precision editing versus nuclease approaches

Not financial advice — research and opinion only. Disclosures